BridgeBio Pharma

BBIO

Market cap $9.84B

Overview Fund Activity

51.47 USD

+0.26

0.51%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

51.79

+0.32

0.62%

1 day

0.51%

5 days

-4.84%

1 month

0.29%

3 months

25.11%

6 months

55.92%

Year to date

82.52%

1 year

96.53%

5 years

39.15%

10 years

86.82%

About: BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Employees: 730

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 13 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

388% more call options, than puts

Call options by funds: $515M | Put options by funds: $105M

168% more first-time investments, than exits

New positions opened: 91 | Existing positions closed: 34

30% more repeat investments, than reductions

Existing positions increased: 135 | Existing positions reduced: 104

27% more capital invested

Capital invested by funds: $6.41B [Q1] → $8.15B (+$1.75B) [Q2]

18% more funds holding

Funds holding: 302 [Q1] → 356 (+54) [Q2]

2.08% more ownership

Funds ownership: 97.36% [Q1] → 99.44% (+2.08%) [Q2]

6% less funds holding in top 10

Funds holding in top 10: 18 [Q1] → 17 (-1) [Q2]

See Fund Rankings

Research analyst outlook

13 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$49

5% downside

Avg. target

$68

32% upside

High target

$95

85% upside

13 analyst ratings

13 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Raghuram Selvaraju	$70	Buy Reiterated	15 Sep 2025
UBS Eliana Merle	$82	Buy Maintained	12 Sep 2025
JP Morgan Anupam Rama	$70	Overweight Maintained	3 Sep 2025
Scotiabank Greg Harrison	$57	Sector Outperform Maintained	6 Aug 2025
Oppenheimer Leland Gershell	$61	Outperform Maintained	6 Aug 2025
Cantor Fitzgerald Josh Schimmer	$95	Overweight Reiterated	29 Jul 2025
Truist Securities Danielle Brill	$66	Buy Initiated	21 Jul 2025
Piper Sandler Biren Amin	$68	Overweight Maintained	14 Jul 2025
Jefferies Andrew Tsai	$70	Buy Initiated	14 Jul 2025
Citigroup David Lebowitz	$67	Buy Maintained	11 Jul 2025
Wells Fargo Tiago Fauth	$76	Overweight Maintained	30 Jun 2025
B of A Securities Geoff Meacham	$54	Buy Maintained	25 Jun 2025
Wolfe Research Andy Chen	$49	Outperform Initiated	17 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 10 articles about BBIO published over the past 30 days

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that the compensation committee of its board of directors (the “committee”) approved equity grants in the form of restricted stock units (“RSUs”) to new employees under the Company's Amended and Restated 2019 Inducement Equity Plan (the “Plan”). The committee approved: (i) on September 5, 2025, RSU grants covering an aggregate of 33,684 shares of the Company's common stock to 13 new employees; (ii) on August 4, 2025, RSU grants covering an aggregate of 32,145 shares of the Company's common stock to 16 new employees; and (iii) on July 14, 2025, RSU grants covering an aggregate of 73,991 shares of the Company's common stock to 20 new employees. One-fourth of the shares underlying these RSUs will vest on August 16, 2026, with the remaining shares vesting in equal quarterly installments over the following three years, subject to continued employment with BridgeBio or its subsidiaries on each applicable vesting date. Separately, on June 6, 2025, the committee approved RSU grants covering an aggregate of 98,348 shares of the Company's common stock to 25 new employees, with one-fourth of the shares vesting on May 16, 2026, and the balance vesting in equal quarterly installments over the following three years, also subject to continued employment with BridgeBio or its subsidiaries on each applicable vesting date.

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma, Inc. (BBIO) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar Call (Transcript)

BridgeBio Pharma, Inc. (NASDAQ:BBIO ) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar Call Company Participants Ananth Sridhar Conference Call Participants Rachel Gafni Scott Adler Tyler Van Buren - TD Cowen, Research Division Biren Amin - Piper Sandler & Co., Research Division Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Lin Tsai - Jefferies LLC, Research Division Danielle Brill Bongero - Truist Securities, Inc., Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Presentation Operator Thank you for standing by, and welcome to the Autosomal Dominant Hypocalcemia Type 1 investor webinar. [Operator Instructions] I'd now like to turn the call over to Ananth Sridhar.

BridgeBio Pharma, Inc. (BBIO) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar Call (Transcript)

BridgeBio Pharma, Inc. (BBIO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

BridgeBio Pharma, Inc. (NASDAQ:BBIO ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 3:20 PM EDT Company Participants Neil Kumar - Co-Founder, CEO & Director Presentation Unknown Analyst Good afternoon. Welcome, everyone.

BridgeBio Pharma, Inc. (BBIO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism

- 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal reference range within 5 days of encaleret treatment initiation compared to 0% of participants on conventional therapy at baseline

Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism

BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET

PALO ALTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Wednesday, September 10, 2025 at 8:00 am ET with Rachel Gafni, M.D., Senior Research Physician at the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health (NIH) and Principal Investigator and Steering Committee Co-Chair for CALIBRATE, the Company's Phase 3 clinical trial for autosomal dominant hypocalcemia type 1 (ADH1).

BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET

BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism

PALO ALTO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that an oral presentation of Phase 2 data in post-surgical hypoparathyroidism and two poster sessions on skeletal dysplasia data will be shared at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025, taking place in Seattle, WA from September 5 - 8, 2025.

BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ATTR-CM

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

BridgeBio to Participate in September Investor Conferences

PALO ALTO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host fireside chats at the following healthcare investor conferences:

BridgeBio to Participate in September Investor Conferences

BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025

PALO ALTO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire oral presentation on additional open-label extension data from ATTRibute-CM and two ePosters with ATTRibute-CM data at Month 30 will be shared at the European Society of Cardiology (ESC) Congress 2025, taking place in Madrid, Spain from August 29 - September 1, 2025.

BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025

‘BUY THAT THING': Historically undervalued stock now has value, says wealth expert

Aquinas Wealth Advisors CEO Chris McMahon discusses the state of the economy, the success of healthcare stocks and more on ‘Making Money.' #foxbusiness #fox #usa #us #news #breakingnews #MakingMoney #ChrisMcMahon #WealthExpert #Stocks #StockMarket #Investing #Investment #Finance #Business #Economy #USEconomy #Markets #Alcohol #Liquor #Health #Healthcare #Water #Consumers #Money #WallStreet #BusinessNews

‘BUY THAT THING': Historically undervalued stock now has value, says wealth expert

See News Rankings

Charts implemented using Lightweight Charts™